Repeated Chatbot Questionnaires to Spot Heart Failure Getting Worse Early
Looks at repeated symptom questionnaires, answered by chatbot, in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Patient-Reported Health Status Assessment Using the KCCQ for Early Detection of Heart Failure Worsening
Key facts
- Where
- Moscow, RussiaSee the site
Where in Russia
- I.M. Sechenov First Moscow State Medical University (Sechenov University)Moscow, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- I.M. Sechenov First Moscow State Medical University
- Trial code
- NCT07552142
- Record updated
- 27 April 2026
- Original description
This observational feasibility study aims to assess (i) how practical and acceptable repeated KCCQ assessments are; (ii) the connection between changes over time in KCCQ scores and signs of congestion; and (iii) clinical outcomes, including worsening heart failure events or cardiovascular death (CVD), and the time between 5- and 10-point KCCQ changes and clinical events.Read full original descriptionShow less
Patient-Reported Health Status Assessment Using the Kansas City Cardiomyopathy Questionnaire for Early Detection of Heart Failure Worsening
This observational feasibility study aims to assess (i) how practical and acceptable repeated KCCQ assessments are; (ii) the connection between changes over time in KCCQ scores and signs of congestion; and (iii) clinical outcomes, including worsening heart failure events or cardiovascular death (CVD), and the time between 5- and 10-point KCCQ changes and clinical events.
Inclusion: Established diagnosis of chronic HF with reduced, mildly reduced, or preserved ejection fraction, NYHA II-III; History of heart failure (HF) hospitalization within the last 6 months before enrollment, defined as the presence of dyspnea, elevated NT-proBNP ≥300 pg/mL (sinus rhythm) or ≥600 pg/mL (if AF), and 2 of the following: i. Rales on chest auscultation or signs of congestion on X-ray/CT scan; ii. Peripheral Oedema; iii. Loop diuretics IV at admission; Free of signs and symptoms of congestion, defined as JVP of <8 cm, with no orthopnea, pulmonary rales, and with trace peripheral edema or no edema; Stable doses of oral loop diuretics, if prescribed; Ability to provide informed consent.
Exclusion: Previous cardiac transplantation and candidates for heart transplantation; Significant drug or alcohol abuse during the last year; Acute coronary syndrome, cardiac surgery, pulmonary embolism, cerebrovascular accident, ablation of atrial flutter/fibrillation, valve repair/replacement, implanted cardioverter defibrillator or urgent PCI within the last 3 months; Planned interventions, including major cardiac surgery (coronary artery bypass grafting, valve repair/replacement, ventricular assist device, cardiac transplantation), coronary revascularization, implantation of a cardiac device or ablation of atrial flutter/fibrillation during the study; Complex congenital heart disease; Heart failure due to active myocarditis, pericardial constriction, known hypertrophic cardiomyopathy or cardiac amyloidosis, or uncorrected severe valvular heart disease; Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease; Cirrhosis, chronic active hepatitis, or other severe hepatic disease; Any active cancer; Hemodialysis; Infective endocarditis.